Highlights
The no-reflow phenomenon occurs in approximately 20-30% of patients even after technically successful endovascular thrombectomy (eTICI 2c-3).
Serial perfusion MRI demonstrates that no-reflow is not a static event; it can persist, resolve, or newly develop within 24 to 48 hours post-procedure.
Global no-reflow identified at the 2-hour mark is a potent predictor of subsequent infarct growth.
The presence of no-reflow at 24-48 hours is strongly associated with lower odds of achieving functional independence at 3 months.
Introduction: The Paradox of Successful Recanalization
In the modern era of stroke management, endovascular thrombectomy (EVT) has revolutionized the treatment of acute large vessel occlusion (LVO). Clinicians frequently achieve high rates of technical success, defined by the expanded Treatment in Cerebral Ischemia (eTICI) scores of 2b, 2c, or 3. However, a frustrating clinical paradox remains: a significant portion of patients fail to recover despite the successful removal of the primary thrombus. This discrepancy between macrovascular recanalization and microvascular reperfusion is often attributed to the no-reflow phenomenon.
Historically recognized in myocardial infarction, the no-reflow phenomenon in the brain refers to the failure of tissue-level perfusion despite the restoration of flow in the upstream large artery. While its existence has been documented, its temporal dynamics—how it changes over the critical first 48 hours—have remained poorly understood until now. A new study published in Neurology by Ng et al. provides critical insights into this phenomenon using serial perfusion MRI, offering a window into the microvascular hurdles that follow successful EVT.
Study Design and Methodology
This multicenter prospective observational study, registered under ACTRN12624000629538, enrolled 67 consecutive adult patients with acute anterior LVO. The researchers focused on a subset of 29 patients who achieved near-complete or complete angiographic reperfusion (eTICI 2c-3) to isolate the no-reflow phenomenon from incomplete mechanical recanalization.
Imaging Protocol and Definitions
The study utilized serial post-thrombectomy perfusion MRI at two distinct time points: Time Point 1 (TP1) at approximately 2 hours post-procedure, and Time Point 2 (TP2) at 24 to 48 hours. This serial approach is vital for capturing the evolution of tissue perfusion over time. No-reflow was rigorously defined as visually detectable hypoperfusion within the infarct area, characterized by a greater than 15% reduction in interside median relative cerebral blood volume (rCBV) or flow (rCBF). The researchers assessed these changes both globally across the entire diffusion-weighted imaging (DWI)-positive lesion and within specific subregions, including the early ischemic core and the area of infarct growth.
Key Findings: The Fluid Nature of Microvascular Reperfusion
The results of the study underscore that no-reflow is a frequent and highly dynamic complication of ischemic stroke. Among the 29 patients with successful recanalization, 21% exhibited no-reflow at TP1, and 24% showed global no-reflow at TP2.
Temporal Patterns of No-Reflow
One of the most significant contributions of this research is the mapping of how perfusion deficits evolve. Between the 2-hour and 48-hour marks, the study observed four distinct patterns:
1. Persistence: In three patients, the hypoperfusion remained stable across both time points.
2. Resolution: Two patients showed no-reflow at TP1 that resolved by TP2, suggesting that microvascular obstruction can be transient.
3. Progression: One patient demonstrated an worsening of the perfusion deficit over time.
4. Delayed Development: Most intriguingly, three patients who had adequate perfusion at 2 hours developed new no-reflow deficits by the 24-48 hour mark.
This variability suggests that the microvasculature is in a state of flux following the massive physiological stress of ischemia and sudden reperfusion.
Impact on Tissue Fate and Clinical Recovery
The clinical implications of these perfusion patterns are profound. Global no-reflow at TP1 was significantly associated with greater infarct growth at TP2, with a median difference of 25.02 mL (95% CI 5.60-44.43, p = 0.01). This suggests that the failure to reperfuse the microvasculature early leads to the progressive death of tissue that might have otherwise been salvageable.
Furthermore, global no-reflow at the later time point (TP2) was a strong predictor of clinical failure. Patients with no-reflow at 24-48 hours had significantly lower odds of achieving a favorable clinical outcome (modified Rankin Scale score 0-1 at 3 months), with an odds ratio of 0.14 (95% CI 0.02-0.84, p = 0.03). This data reinforces the idea that microvascular health is a primary determinant of long-term neurologic recovery.
Expert Commentary: Mechanistic Insights and Biological Plausibility
The findings by Ng et al. align with emerging theories on ischemia-reperfusion injury. The no-reflow phenomenon is likely driven by a multifaceted cascade of events. At the cellular level, pericytes—contractile cells wrapped around capillaries—have been shown in animal models to constrict in response to oxidative stress, effectively “choking” the microcirculation even after the large artery is opened. Other contributing factors include endothelial cell swelling (blebbing), the formation of microthrombi (distal embolization of the original clot or de novo formation), and the infiltration of inflammatory cells that increase blood viscosity and cause mechanical plugging.
The observation that no-reflow can develop late (after 2 hours) suggests that secondary inflammatory responses or delayed cerebral edema may play a role. Conversely, the resolution of no-reflow in some patients provides hope; it indicates that the microvascular obstruction is not always permanent and may be reversible with the right therapeutic intervention.
From a clinical standpoint, these results suggest that our definition of “successful” treatment needs to evolve. We can no longer stop at the angiogram. The use of early post-EVT perfusion imaging could help identify patients who require “adjunctive reperfusion” strategies. Potential treatments being investigated include intra-arterial vasodilators (such as verapamil or adenosine), anti-thrombotic agents targeting microvascular plugs, and neuroprotective drugs designed to stabilize the blood-brain barrier and reduce pericyte constriction.
Conclusion: Moving Toward “Full” Reperfusion
The study by Ng and colleagues provides a compelling argument for the importance of the microvasculature in stroke recovery. By demonstrating that no-reflow is a dynamic process associated with both infarct expansion and poor functional outcomes, the research highlights a critical unmet need in stroke care. The findings suggest that the 2-to-48-hour window following thrombectomy is a period of high vulnerability and potential opportunity. Future clinical trials should focus on therapies that target these temporal dynamics, aiming not just for macrovascular recanalization, but for true, sustained microvascular reperfusion.
Funding and Trial Registration
This study was supported by various institutional grants and was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12624000629538). The authors declare no competing financial interests that influenced the results of this study.
References
1. Ng FC, Rivet S, Churilov L, et al. Temporal Dynamics of the No-Reflow Phenomenon on Serial Perfusion MRI After Thrombectomy. Neurology. 2026;106(7):e214673.
2. Kloner RA, Ganote CE, Jennings RB. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54(6):1496-1508.
3. Hall CN, Reynell C, Gesslein B, et al. Capillary pericytes regulate cerebral blood flow in health and disease. Nature. 2014;508(7494):55-60.
4. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723-1731.